Announcements Trials
Browse Landscape

Phase

Phase 1 22Phase 1/2 5Phase NA 3Phase 2 1

Status

Unknown 3Recruiting 2

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Other solid neoplasm 5

Conditions

Advanced Solid Tumor 104Advanced Solid Tumors 92Solid Tumor 69Mesothelioma 42Mesothelioma, Malignant 41Solid Tumors 37Carcinoma, Non-Small-Cell Lung 25Solid Tumor, Adult 22Stomach Neoplasms 15Ovarian Neoplasms 15Esophageal Neoplasms 15Melanoma 13Colorectal Neoplasms 13Carcinoma, Renal Cell 13Endometrial Neoplasms 11Unspecified Adult Solid Tumor, Protocol Specific 10Pancreatic Neoplasms 10Neoplasms 10Neoplasm Metastasis 10Advanced Malignant Solid Tumor 10Uterine Cervical Neoplasms 9Malignant Solid Tumor 9Lung Neoplasms 9Breast Neoplasms 9Triple Negative Breast Neoplasms 8Squamous Cell Carcinoma of Head and Neck 8Sarcoma 8Advanced or Metastatic Solid Tumors 8Carcinoma, Hepatocellular 7Small Cell Lung Carcinoma 6

Interventions

Clinical Trials, Phase II as Topic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × Advanced Malignant Solid Tumors × Other solid neoplasm × Clear all
NCT06499350 2026-03-10

A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors

FindCure Biosciences (ZhongShan) Co., Ltd.

Phase 1/2 Recruiting
33 enrolled
Other solid neoplasm

Advanced Malignant Solid Tumors

NCT06464055 2025-02-10

A Study of GQ1010 in Subjects With Advanced Solid Tumors

GeneQuantum Healthcare (Suzhou) Co., Ltd.

Phase 1/2 Recruiting
260 enrolled
Other solid neoplasm

Advanced Malignant Solid Tumors

NCT05338957 2022-12-01

A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors.

Shanghai Miracogen Inc.

Phase 1/2 Unknown
30 enrolled
Other solid neoplasm

Advanced Malignant Solid Tumors

NCT05478785 2022-07-29

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Efficacy of Cisplatin Micelle Injection (HA132) in Patients With Advanced Malignant Solid Tumors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 1/2 Unknown
126 enrolled
Other solid neoplasm

Advanced Malignant Solid Tumors

NCT04226066 2020-12-07

Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors

Tasly Tianjin Biopharmaceutical Co., Ltd.

Phase 1/2 Unknown
69 enrolled
Other solid neoplasm

Advanced Malignant Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡